Gastrointestinal stromal tumours-an update for histopathologists

Histopathology

Volumn 59, Issue 5, 2011, Pages 807-821

  Wong, Newton A C S ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

BRAF; Carney syndrome; CD117; DOG1; Gastrointestinal stromal tumour; Imatinib; Insulin growth factor 1 receptor; KIT; Paediatric; PDGFRA; Prognosis; Succinate dehydrogenase; Sunitinib

Indexed keywords

B RAF KINASE; CARBONATE DEHYDRATASE II; DASATINIB; DOG1 PROTEIN; ESTROGEN RECEPTOR ALPHA; FLUORODEOXYGLUCOSE F 18; HEAT SHOCK PROTEIN; IMATINIB; NESTIN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN; PROTEIN KINASE C THETA; SOMATOMEDIN BINDING PROTEIN 1; STEM CELL FACTOR RECEPTOR; SUCCINATE DEHYDROGENASE; SUNITINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTIGEN RETRIEVAL; CANCER CLASSIFICATION; CANCER GROWTH; CANCER LOCALIZATION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARNEY COMPLEX; CHILDHOOD CANCER; CLINICAL PRACTICE; CYTOPLASM; DISEASE MARKER; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG RESISTANCE; DUODENUM; ENDOMETRIAL STROMAL TUMOR; EXON; FALSE POSITIVE RESULT; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; ILEUM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; JEJUNUM; LYMPH NODE METASTASIS; MESENTERY; METASTASIS; MITOSIS; NEUROFIBROMATOSIS; OMENTUM; PARAGANGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM; REVIEW; STOMACH; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR VOLUME;

GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL;

EID: 81555216746     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03812.x     Document Type: Review

References (94)

1. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103; 821-829.
2. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int. J. Cancer 2005; 117; 289-293.
3. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 2002; 33; 459-465.
4. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53; 245-266.
5. Rutkowski P, Debiec-Rychter M, Ruka W. Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol. Diagn. Ther. 2008; 12; 131-143.
6. NHS National Institute for Clinical Excellence. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours. Technology Appraisal 86, October 2004. Available at: (accessed 2 December 2010).
7. Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann. Oncol. 2005; 16; 566-578.
8. Wong NA, Melegh Z. Antigen retrieval and primary antibody type affect sensitivity but not specificity of CD117 immunohistochemistry. Histopathology 2009; 54; 529-538.
9. Tsujimura T, Makiishi-Shimobayashi C, Lundkvist J et al. Expression of the intermediate filament nestin in gastrointestinal stromal tumors and interstitial cells of Cajal. Am. J. Pathol. 2001; 158; 817-823.
10. Parkkila S, Lasota J, Fletcher JA et al. Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod. Pathol. 2010; 23; 743-750.
11. Motegi A, Sakurai S, Nakayama H, Sano T, Oyama T, Nakajima T. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol. Int. 2005; 55; 106-112.
12. Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am. J. Surg. Pathol. 2009; 33; 437-446.
13. Espinosa I, Lee CH, Kim MK et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am. J. Surg. Pathol. 2008; 32; 210-218.
14. Sarlomo-Rikala M, Tsujimura T, Lendahl U, Miettinen M. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS 2002; 110; 499-507.
15. Novelli M, Rossi S, Rodriguez-Justo M et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010; 57; 259-270.
16. Wong NA, Shelley-Fraser G. Specificity of DOG1 (K9 clone) and protein kinase C theta (clone 27) as immunohistochemical markers of gastrointestinal stromal tumour. Histopathology 2010; 57; 250-258.
17. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am. J. Surg. Pathol. 2009; 33; 1401-1408.
18. Lopes LF, West RB, Bacchi LM, van de Rijn M, Bacchi CE. DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): comparison between 2 different antibodies. Appl. Immunohistochem. Mol. Morphol. 2010; 18; 333-337.
19. West RB, Corless CL, Chen X et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am. J. Pathol. 2004; 165; 107-113.
20. Gomez-Pinilla PJ, Gibbons SJ, Bardsley MR et al. Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract. Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 296; G1370-G1381.
21. Kimura W, Ma J, Takeshita A et al. Analysis of c-kit protein expression in pancreatic neoplasms and its implication for prognosis. Hepatogastroenterology 2007; 54; 2203-2208.
22. Preto A, Moutinho C, Velho S et al. A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. Virchows Arch. 2007; 450; 619-626.
23. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol. 2006; 59; 557-563.
24. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv. Anat. Pathol. 2009; 16; 196-203.
25. Antonescu CR, Sommer G, Sarran L et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin. Cancer Res. 2003; 9; 3329-3337.
26. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am. J. Surg. Pathol. 2006; 30; 477-489.
27. Pauls K, Merkelbach-Bruse S, Thal D, Buttner R, Wardelmann E. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology 2005; 46; 166-175.
28. Lasota J, Wang ZF, Sobin LH, Miettinen M. Gain-of-function PDGFRA mutations, earlier reported in gastrointestinal stromal tumors, are common in small intestinal inflammatory fibroid polyps. A study of 60 cases. Mod. Pathol. 2009; 22; 1049-1056.
29. Schildhaus HU, Cavlar T, Binot E, Buttner R, Wardelmann E, Merkelbach-Bruse S. Inflammatory fibroid polyps harbour mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene. J. Pathol. 2008; 216; 176-182.
30. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J. Invest. Dermatol. 2010; 130; 20-27.
31. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 2006; 23; 70-83.
32. Agaram NP, Laquaglia MP, Ustun B et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin. Cancer Res. 2008; 14; 3204-3215.
33. Zhang L, Smyrk TC, Young WF Jr, Stratakis CA, Carney JA. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am. J. Surg. Pathol. 2010; 34; 53-64.
34. Goh BK, Chow PK, Yap WM et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann. Surg. Oncol. 2008; 15; 2153-2163.
35. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 2008; 39; 1411-1419.
36. Gold JS, Gonen M, Gutierrez A et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009; 10; 1045-1052.
37. Gastrointestinal stromal tumour (GIST). In Sobin L, Gospodarowicz M, Wittekind C eds. TNM classification of malignant tumour, 7th edn. Oxford: Wiley-Blackwell, 2010; 78-81.
38. Demetri GD, von MM, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347; 472-480.
39. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364; 1127-1134.
40. Van Glabbeke M, Verweij J, Casali PG et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J. Clin. Oncol. 2005; 23; 5795-5804.
41. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 2008; 26; 5352-5359.
42. Montemurro M, Schoffski P, Reichardt P et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur. J. Cancer 2009; 45; 2293-2297.
43. Dewaele B, Wasag B, Cools J et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin. Cancer Res. 2008; 14; 5749-5758.
44. DeMatteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373; 1097-1104.
45. Debiec-Rychter M, Sciot R, Le CA et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 2006; 42; 1093-1103.
46. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 2008; 26; 5360-5367.
47. Prenen H, Cools J, Mentens N et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin. Cancer Res. 2006; 12; 2622-2627.
48. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 2005; 23; 5357-5364.
49. Liegl B, Kepten I, Le C et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 2008; 216; 64-74.
50. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res. 2006; 12; 1743-1749.
51. Bumming P, Andersson J, Meis-Kindblom JM et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br. J. Cancer 2003; 89; 460-464.
52. Abdulkader I, Cameselle-Teijeiro J, Forteza J. Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour. Histopathology 2005; 46; 470-472.
53. Pauwels P, Debiec-Rychter M, Stul M, De WI, van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 2005; 47; 41-47.
54. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13(Suppl. 2); 8-13.
55. Mabille M, Vanel D, Albiter M et al. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under imatinib therapy requires different criteria of radiological evaluation (size is not everything!). Eur. J. Radiol. 2009; 69; 204-208.
56. Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am. J. Surg. Pathol. 2009; 33; 218-226.
57. Thalheimer A, Schlemmer M, Bueter M et al. Familial gastrointestinal stromal tumors caused by the novel KIT exon 17 germline mutation N822Y. Am. J. Surg. Pathol. 2008; 32; 1560-1565.
58. Kleinbaum EP, Lazar AJ, Tamborini E et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int. J. Cancer 2008; 122; 711-718.
59. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J. Intern. Med. 2009; 266; 43-52.
60. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am. J. Surg. Pathol. 2006; 30; 90-96.
61. Takazawa Y, Sakurai S, Sakuma Y et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am. J. Surg. Pathol. 2005; 29; 755-763.
62. Pasini B, McWhinney SR, Bei T et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur. J. Hum. Genet. 2008; 16; 79-88.
63. Agaimy A, Pelz AF, Corless CL et al. Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. Oncol. Rep. 2007; 18; 9-15.
64. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am. J. Med. Genet. 2002; 108; 132-139.
65. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am. J. Surg. Pathol. 2005; 29; 1373-1381.
66. Prakash S, Sarran L, Socci N et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J. Pediatr. Hematol. Oncol. 2005; 27; 179-187.
67. Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC. Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer 2004; 101; 39-50.
68. Miettinen M, Monihan JM, Sarlomo-Rikala M et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am. J. Surg. Pathol. 1999; 23; 1109-1118.
69. Lee CH, Lin YH, Lin HY, Lee CM, Chu JS. Gastrointestinal stromal tumor of the prostate: a case report and literature review. Hum. Pathol. 2006; 37; 1361-1365.
70. Kang SH, Kim MJ, Park MG et al. Extragastrointestinal stromal tumor presenting as a scrotal mass: an unusual case. Asian J. Androl. 2007; 9; 275-279.
71. Krska Z, Peskova M, Povysil C, Horejs J, Sedlackova E, Kudrnova Z. GIST of pancreas. Prague Med. Rep. 2005; 106; 201-208.
72. Peerlinck ID, Irvin TT, Sarsfield PT, Harington JM. GIST (gastro-intestinal stromal tumour) of the gallbladder: a case report. Acta Chir. Belg. 2004; 104; 107-109.
73. Luo XL, Liu D, Yang JJ, Zheng MW, Zhang J, Zhou XD. Primary gastrointestinal stromal tumor of the liver: a case report. World J. Gastroenterol. 2009; 15; 3704-3707.
74. Zhang W, Peng Z, Xu L. Extragastrointestinal stromal tumor arising in the rectovaginal septum: report of an unusual case with literature review. Gynecol. Oncol. 2009; 113; 399-401.
75. Foster R, Solano S, Mahoney J, Fuller A, Oliva E, Seiden MV. Reclassification of a tubal leiomyosarcoma as an eGIST by molecular evaluation of c-KIT. Gynecol. Oncol. 2006; 101; 363-366.
76. Wingen CB, Pauwels PA, Debiec-Rychter M, van Gemert WG, Vos MC. Uterine gastrointestinal stromal tumour (GIST). Gynecol. Oncol. 2005; 97; 970-972.
77. Irving JA, Lerwill MF, Young RH. Gastrointestinal stromal tumors metastatic to the ovary: a report of five cases. Am. J. Surg. Pathol. 2005; 29; 920-926.
78. Wong NA, Melegh Z. Gastrointestinal stromal tumours can express CD10 and epithelial membrane antigen but not oestrogen receptor or HMB45. Histopathology, in press.
79. Brodsky SV, Gimenez C, Ghosh C, Melamed M, Ramaswamy G. Estrogen and progesterone receptors expression in gastrointestinal stromal tumors and intramural gastrointestinal leiomyomas. Int. J. Gastrointest. Cancer 2006; 37; 129-132.
80. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod. Pathol. 2000; 13; 1134-1142.
81. Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod. Pathol. 2001; 14; 465-471.
82. Butnor KJ, Burchette JL, Robboy SJ. Progesterone receptor activity in leiomyomatosis peritonealis disseminata. Int. J. Gynecol. Pathol. 1999; 18; 259-264.
83. Paal E, Miettinen M. Retroperitoneal leiomyomas: a clinicopathologic and immunohistochemical study of 56 cases with a comparison to retroperitoneal leiomyosarcomas. Am. J. Surg. Pathol. 2001; 25; 1355-1363.
84. Long KB, Butrynski JE, Blank SD et al. Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation. Am. J. Surg. Pathol. 2010; 34; 907-912.
85. Agaimy A, Terracciano LM, Dirnhofer S et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J. Clin. Pathol. 2009; 62; 613-616.
86. Hostein I, Faur N, Primois C et al. BRAF mutation status in gastrointestinal stromal tumors. Am. J. Clin. Pathol. 2010; 133; 141-148.
87. Vultur A, Villanueva J, Herlyn M. BRAF inhibitor unveils its potential against advanced melanoma. Cancer Cell 2010; 18; 301-302.
88. Tarn C, Rink L, Merkel E et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc. Natl. Acad. Sci. U S A 2008; 105; 8387-8392.
89. Pantaleo MA, Astolfi A, Di BM et al. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int. J. Cancer 2009; 125; 2991-2994.
90. Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int. J. Cancer 2010; 127; 2718-2722.
91. Braconi C, Bracci R, Bearzi I et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann. Oncol. 2008; 19; 1293-1298.
92. van Nederveen FH, Gaal J, Favier J et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009; 10; 764-771.
93. Gill AJ, Chou A, Vilain R et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am. J. Surg. Pathol. 2010; 34; 636-644.
94. Gaal J, Stratakis CA, Carney JA et al. SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod. Pathol. 2011; 24; 147-151.